Financial reports
10-Q
2024 Q1
Quarterly report
15 May 24
ARS
2023 FY
Annual report to shareholders
15 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
Current reports
8-K
Departure of Directors or Certain Officers
5 Jun 24
8-K
Results of Operations and Financial Condition
15 May 24
8-K
Results of Operations and Financial Condition
1 Apr 24
8-K
Other Events
13 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Mar 24
8-K
Increasing physician interest, newly approved reimbursement code driving growth
5 Mar 24
8-K
Departure of Directors or Certain Officers
31 Jan 24
8-K
Departure of Directors or Certain Officers
5 Dec 23
8-K
Regulation FD Disclosure
30 Nov 23
8-K
Results of Operations and Financial Condition
15 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
5 Jun 24
424B3
Prospectus supplement
22 May 24
424B3
Prospectus supplement
22 May 24
424B3
Prospectus supplement
16 Apr 24
POS AM
Prospectus update (post-effective amendment)
5 Apr 24
S-1
IPO registration
4 Apr 24
POS AM
Prospectus update (post-effective amendment)
1 Apr 24
D
$2.62 mm in equity / options / securities to be acquired, sold $2.62 mm, 3 investors
20 Mar 24
424B5
Prospectus supplement for primary offering
8 Mar 24
424B5
Prospectus supplement for primary offering
7 Mar 24
Other
EFFECT
Notice of effectiveness
17 Apr 24
EFFECT
Notice of effectiveness
8 Apr 24
EFFECT
Notice of effectiveness
28 Nov 23
CORRESP
Correspondence with SEC
22 Nov 23
UPLOAD
Letter from SEC
21 Nov 23
EFFECT
Notice of effectiveness
30 Aug 22
CORRESP
Correspondence with SEC
26 Aug 22
CORRESP
Correspondence with SEC
26 Aug 22
CORRESP
Correspondence with SEC
25 Aug 22
CORRESP
Correspondence with SEC
25 Aug 22